Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Back to Search
Print
Bookmark Trial

NCT00396448

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Peoria, Arizona, 85381, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Obese adults with a body mass index > or = 30 kg/m ; > or = 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pregnancy


- Diabetes


- Adults with serious or unstable current or past medical conditions

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

ObesityA 26-Week, 2-Part Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
NCT04707313
  1. Winnipeg, Manitoba
  2. Quebec,
  3. Anniston, Alabama
  4. Anaheim, California
  5. Los Angeles, California
  6. Orlando, Florida
  7. Gurnee, Illinois
  8. Evansville, Indiana
  9. Valparaiso, Indiana
  10. Topeka, Kansas
  11. Louisville, Kentucky
  12. Omaha, Nebraska
  13. Omaha, Nebraska
  14. Hickory, North Carolina
  15. Raleigh, North Carolina
  16. Salisbury, North Carolina
  17. Wilmington, North Carolina
  18. Fargo, North Dakota
  19. Cleveland, Ohio
  20. Moncks Corner, South Carolina
  21. North Charleston, South Carolina
  22. Summerville, South Carolina
  23. Summerville, South Carolina
  24. Bristol, Tennessee
  25. Bristol, Tennessee
  26. Bristol, Tennessee
  27. Knoxville, Tennessee
  28. Brampton, Ontario
  29. London, Ontario
  30. Toronto, Ontario
  31. Chicoutimi, Quebec
  32. Sherbrooke, Quebec
  33. Quebec,
  34. Suita-shi, Osaka
  35. Chuo-ku, Tokyo
  36. Chuo-ku, Tokyo
  37. Shinjuku-ku, Tokyo
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityStudy To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
NCT04621227
  1. Anaheim, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
OBESITYSTUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
NCT04616339
  1. Brussels, Bruxelles-capitale, Région DE
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityPharmacokinetics Of Tigecycline In Morbidly Obese Subjects
NCT01560143
  1. Albany, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
Official Title  ICMJE A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects
Brief Summary The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
Detailed Description The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No safety issues were involved in the termination decision.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Drug: CP-945,598 Treatment B
    Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
  • Drug: CP-945,598 Treatment A
    Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
  • Drug: Placebo
    Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Study Arms  ICMJE
  • Experimental: CP-945,598 Treatment B
    Intervention: Drug: CP-945,598 Treatment B
  • Experimental: CP-945,598 Treatment A
    Intervention: Drug: CP-945,598 Treatment A
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: October 28, 2009)		1253
Original Enrollment  ICMJE
 (submitted: November 6, 2006)		1500
Actual Study Completion Date  ICMJE February 2009
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Obese adults with a body mass index > or = 30 kg/m ; > or = 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia

Exclusion Criteria:

  • Pregnancy
  • Diabetes
  • Adults with serious or unstable current or past medical conditions
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Chile,   France,   Germany,   Korea, Republic of,   Mexico,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00396448
Other Study ID Numbers  ICMJE A5351019
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP